Carisma Therapeutics, Inc. (CARM)

Market Cap	59.82M
Revenue (ttm)	15.07M
Net Income (ttm)	-81.22M
Shares Out	41.54M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,445,481
Open	1.610
Previous Close	1.670
Day's Range	1.440 - 1.660
52-Week Range	0.990 - 9.766
Beta	n/a
Analysts	Strong Buy
Price Target	9.00 (+525.0%)
Earnings Date	Aug 8, 2024

About CARM

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: CARM

Financial Performance

In 2023, CARM's revenue was $14.92 million, an increase of 51.71% compared to the previous year's $9.83 million. Losses were -$86.88 million, 41.9% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CARM stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 525.00% from the latest price.

Price Target

$9.0

(525.00% upside)

Analyst Consensus: Strong Buy